Kinetic GFR and AKI Prognosis

Kinetic Estimated Glomerular Filtration Rate (KeGFR) and Acute Kidney Injury (AKI) Prognosis

Understanding how kidney function changes over time is essential for clinicians managing critically ill patients. The kinetic estimated glomerular filtration rate (KeGFR) integrates the dynamics of serum creatinine (SCr) to provide a more responsive measure of renal function than static eGFR. This course explains the key concepts, prognostic implications, and practical applications of KeGFR in the context of AKI, based on recent research findings.

1. What Is KeGFR?

KeGFR is a formula that estimates the glomerular filtration rate by accounting for the rate of change in serum creatinine between two measurements. Unlike traditional eGFR equations, which assume a steady‑state creatinine level, KeGFR incorporates a kinetic component, making it especially useful in acute settings where creatinine is rapidly rising or falling.

• Components of the formula:
  • Baseline serum creatinine (the value before the acute change).
  • Mean serum creatinine between the two measurements.
  • Change in serum creatinine over the time interval.
  • Patient’s body surface area (BSA) to standardize to 1.73 m².
• Not included: Patient’s age is not a direct variable in the kinetic component, although age influences baseline eGFR calculations.

2. KeGFR and the Need for Renal Replacement Therapy (RRT)

One of the most clinically relevant findings is the relationship between a low KeGFR and the likelihood of requiring RRT.

Key Fact

In patients classified as KDIGO stage 3 with a worst KeGFR of < 30 ml/min/1.73 m² (e.g., 28 ml/min/1.73 m²), approximately 44 % will need renal replacement therapy.

This proportion is considerably higher than the often‑cited “rare” or “< 10 %” estimates and underscores the importance of early identification of patients at high risk for dialysis.

• Mnemonic: “44 % = 4‑4, stage 3 = three digits, so 4+4 = 8 ≈ 3 + 5 (approx.) – remember that almost half need RRT.
• Clinical tip: When KeGFR is just below the 30 ml/min threshold, anticipate a substantial probability of RRT and discuss early planning with the multidisciplinary team.

3. KeGFR, AKI Stage, and Hospital Mortality

Mortality risk rises progressively as KeGFR declines, regardless of the AKI stage.

Evidence Summary

Across all AKI stages (1‑3), patients with lower KeGFR values experience higher in‑hospital mortality. This trend is independent of the traditional AKI classification, indicating that KeGFR adds prognostic granularity.

• Mnemonic: “K‑Low → M‑High, in all stages.”
• Visual aid: Imagine a descending staircase of KeGFR; each step down increases the chance of “falling” (i.e., death), no matter where you start.

4. Mortality in AKI Stage 1 with Low KeGFR

Even patients classified as AKI stage 1 can have a markedly increased risk of death if their worst KeGFR falls below 30 ml/min/1.73 m².

Key Statistic

Hospital mortality in this subgroup is approximately 27 %, which is comparable to the mortality observed in patients without AKI but with a similarly low KeGFR.

This finding highlights that a low KeGFR can offset the traditionally “milder” prognosis associated with AKI stage 1.

5. Why Identical Creatinine Increases Yield Different KeGFR Values

Two patients may both show a rise in serum creatinine from 1.0 mg/dL to 1.5 mg/dL, yet their KeGFRs can differ substantially.

Reason

The kinetic component of KeGFR depends on the time interval over which the creatinine change occurs. A rapid rise (e.g., within 12 hours) indicates a more severe decline in renal function than the same rise over 48 hours, resulting in a lower KeGFR.

• Clinical implication: Always record the exact timing of creatinine measurements when calculating KeGFR.

6. Limitations of Baseline Serum Creatinine Estimation

Accurate baseline SCr is crucial for KeGFR calculation, yet the study identified a notable limitation.

Limitation

Baseline serum creatinine was taken as the lowest ICU value, which may underestimate the true pre‑illness baseline, especially in patients who already have chronic kidney disease.

• Resulting bias: Over‑estimation of the creatinine rise and under‑estimation of KeGFR, potentially inflating the perceived severity of AKI.

7. Integrating KeGFR with Traditional AKI Classification

KeGFR does not replace the KDIGO AKI staging system; instead, it provides complementary information.

Best Practice

Use both tools together:

• AKI stage offers a categorical view based on absolute creatinine changes and urine output.
• KeGFR adds a dynamic, quantitative dimension that refines risk stratification for outcomes such as mortality and need for RRT.

When both metrics point toward high risk (e.g., KDIGO stage 3 plus KeGFR < 30 ml/min), clinicians should consider early nephrology consultation and proactive RRT planning.

8. KeGFR’s Impact on Odds of Hospital Death in AKI Stage 2

Multivariate logistic regression analyses demonstrated that a KeGFR of 30–45 ml/min/1.73 m² significantly increases the odds of in‑hospital death for patients with AKI stage 2.

Quantitative Effect

The odds ratio (OR) for mortality rises to approximately 1.62 in this subgroup, indicating a 62 % higher risk compared with patients who have higher KeGFR values.

• Interpretation: Even modest reductions in KeGFR (still above the 30 ml/min threshold) carry a meaningful prognostic penalty.
• Clinical action: Intensify monitoring and consider early interventions for patients with AKI stage 2 whose KeGFR falls into the 30–45 ml/min range.

9. Practical Steps for Clinicians

To incorporate KeGFR into routine practice, follow these steps:

1. Collect two serum creatinine values with a clearly documented time interval (preferably within the first 24 hours of ICU admission).
2. Determine baseline SCr using the lowest pre‑ICU value when available; if not, acknowledge the potential bias.
3. Apply the kinetic formula:
   • KeGFR = (Mean SCr × BSA) / (ΔSCr / Δt) – where ΔSCr is the change in creatinine and Δt is the time in days.
4. Interpret the result in the context of KDIGO stage:
   • KeGFR < 30 ml/min → high risk for RRT and mortality.
   • KeGFR 30–45 ml/min → increased mortality risk, especially in AKI stage 2.
   • KeGFR > 45 ml/min → comparatively lower risk, but still consider trends.
5. Document the combined risk assessment and discuss with the care team.

10. Summary of Key Take‑aways

• KeGFR adds a kinetic perspective to renal function assessment, capturing rapid changes missed by static eGFR.
• In KDIGO stage 3 patients with KeGFR ≈ 28 ml/min, about 44 % will need RRT.
• Mortality rises progressively as KeGFR declines, independent of AKI stage.
• Even AKI stage 1 patients with KeGFR < 30 ml/min face a ~27 % hospital mortality.
• The time interval of creatinine change critically influences KeGFR values.
• Baseline SCr estimation using the lowest ICU value may underestimate true baseline, a recognized limitation.
• KeGFR and AKI classification provide complementary prognostic information; use them together.
• For AKI stage 2, a KeGFR of 30–45 ml/min raises the odds of death to an OR of ~1.62.

By integrating KeGFR into daily practice, clinicians can improve risk stratification, anticipate the need for renal replacement therapy, and tailor interventions to reduce mortality in critically ill patients.